Psychedelics executive order

President Trump signed an executive order on April 18 directing federal agencies to speed psychedelic-drug research and widen access for some patients. (whitehouse.gov) The order tells the Food and Drug Administration to prioritize certain psychedelic drugs that already have Breakthrough Therapy designation, and it tells the Food and Drug Administration and Drug Enforcement Administration to create a pathway for eligible patients to use investigational products under the federal Right to Try law. (whitehouse.gov) The White House said Health and Human Services must put $50 million from the Advanced Research Projects Agency for Health into matching state spending on psychedelic research, and said the attorney general should begin rescheduling reviews after successful Phase 3 trials and Food and Drug Administration approval. (whitehouse.gov) Psychedelics are drugs that can sharply alter perception, mood and sense of time, and the order names ibogaine compounds, psilocybin and similar products as possible treatments for severe mental illness after standard care fails. The policy is aimed especially at veterans with post-traumatic stress disorder, depression and substance-use problems. (whitehouse.gov; usnews.com) The legal change is narrower than many patients may assume. An executive order cannot by itself make psilocybin, MDMA or ibogaine generally legal, and the Drug Enforcement Administration says Schedule I drugs are defined as having no currently accepted medical use and a high potential for abuse. (dea.gov) That means access still runs through research studies, Food and Drug Administration review, and any later rescheduling decisions. Reuters reported federal officials said reclassification could follow successful clinical trials, and Food and Drug Administration Commissioner Marty Makary said decisions on some drugs could come as soon as summer 2026. (usnews.com) The order also lands after a setback for the field’s highest-profile application. In June 2024, a Food and Drug Administration advisory committee reviewed Lykos Therapeutics’ MDMA application for post-traumatic stress disorder, and the agency later declined approval and asked for more evidence on safety and effectiveness. (fda.gov; open.fda.gov) Federal agencies were already moving before Saturday’s order. The Department of Veterans Affairs announced in January 2024 that it would fund studies of certain psychedelic compounds for veterans with post-traumatic stress disorder and depression, and senators Ruben Gallego and David McCormick introduced bipartisan legislation on March 9, 2026, to expand Veterans Affairs research on the treatments. (news.va.gov; gallego.senate.gov) The White House framed the order around a mental-health system it says is failing complex patients, citing more than 14 million U.S. adults with serious mental illness and more than 6,000 veteran suicides a year. The next test is whether faster reviews produce approved drugs, not just more attention. (whitehouse.gov)